Maastricht University psychedelic research trials
Data as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Maastricht University is listed with 3 registered studies counted here, in Maastricht, Netherlands. By compound: 1 psilocybin and 3 LSD. By registry status: 1 recruiting, 1 completed and 1 status not reported. By phase: 1 phase 1, 1 phase 2 and 1 not applicable. Reported start years run from 2021 (earliest) to 2024 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 3 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 1 |
| LSD | 3 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 1 | 33% |
| Completed | 1 | 33% |
| Status not reported | 1 | 33% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 1 | 33% |
| Phase 2 | 1 | 33% |
| Not applicable | 1 | 33% |
Registered studies
All counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Registry dates | Compound |
|---|---|---|---|---|---|
| The Impact of Psilocybin on Pain in Fibromyalgia Patients | NCT06368492 | Recruiting | Not applicable | Source start: 2024-05-03 (actual)Source date detailsStart: 2024-05-03 (precision: day; source type: ACTUAL; actual) Primary completion: 2025-12 (precision: month; source type: ESTIMATED; estimated) Study completion: 2025-12 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.349Z; registry revision: 2025-09-15 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Psilocybin, LSD |
| The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality | NCT05670184 | Status not reported | Phase 1 | Source start: 2023-01-01 (estimated)Source date detailsStart: 2023-01-01 (precision: day; source type: ESTIMATED; estimated) Primary completion: 2024-01-01 (precision: day; source type: ESTIMATED; estimated) Study completion: 2024-01-01 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:16.639Z; registry revision: 2023-01-04 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | LSD |
| Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial | NCT05200936 | Completed | Phase 2 | Source start: 2021-12-17 (actual)Source date detailsStart: 2021-12-17 (precision: day; source type: ACTUAL; actual) Primary completion: 2023-11-06 (precision: day; source type: ACTUAL; actual) Study completion: 2023-12-04 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:16.228Z; registry revision: 2026-02-27 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | LSD |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Country hub: Netherlands